Gabelli Funds LLC cut its position in shares of Chemed Corp. (NYSE:CHE) by 2.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 235,900 shares of the company’s stock after selling 4,700 shares during the period. Gabelli Funds LLC owned 1.48% of Chemed Corp. worth $47,664,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC acquired a new position in shares of Chemed Corp. during the 2nd quarter worth about $120,000. Pacad Investment Ltd. increased its stake in shares of Chemed Corp. by 250.0% during the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after purchasing an additional 500 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Chemed Corp. by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after purchasing an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Chemed Corp. by 12.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after purchasing an additional 83 shares during the last quarter. Finally, MCF Advisors LLC acquired a new position in shares of Chemed Corp. during the 3rd quarter worth about $152,000. Institutional investors own 97.29% of the company’s stock.

Shares of Chemed Corp. (CHE) traded down $3.36 during mid-day trading on Tuesday, hitting $231.65. 127,647 shares of the company traded hands, compared to its average volume of 96,024. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The firm has a market cap of $3,752.17, a P/E ratio of 28.94, a P/E/G ratio of 4.97 and a beta of 1.14.

Chemed Corp. (NYSE:CHE) last posted its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.15. Chemed Corp. had a net margin of 4.62% and a return on equity of 27.69%. The business had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. During the same quarter last year, the company posted $1.73 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. equities research analysts forecast that Chemed Corp. will post 4.73 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Investors of record on Monday, November 13th will be issued a dividend of $0.28 per share. The ex-dividend date is Friday, November 10th. This represents a $1.12 dividend on an annualized basis and a yield of 0.48%. Chemed Corp.’s dividend payout ratio (DPR) is presently 24.89%.

In other news, CEO Kevin J. Mcnamara sold 10,000 shares of Chemed Corp. stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $223.42, for a total value of $2,234,200.00. Following the completion of the transaction, the chief executive officer now owns 170,016 shares in the company, valued at $37,984,974.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Spencer S. Lee sold 1,000 shares of Chemed Corp. stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $228.45, for a total transaction of $228,450.00. Following the completion of the transaction, the executive vice president now owns 36,809 shares of the company’s stock, valued at approximately $8,409,016.05. The disclosure for this sale can be found here. Insiders have sold 13,750 shares of company stock valued at $3,041,293 in the last 90 days. 4.90% of the stock is currently owned by corporate insiders.

Several research analysts have recently weighed in on CHE shares. Zacks Investment Research lowered shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th. Oppenheimer Holdings, Inc. lifted their target price on shares of Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. TheStreet downgraded shares of Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $209.00 target price on shares of Chemed Corp. in a report on Friday, September 1st. Finally, KeyCorp assumed coverage on shares of Chemed Corp. in a report on Monday, August 28th. They set a “sector weight” rating for the company. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $236.00.

WARNING: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/chemed-corp-che-stake-decreased-by-gabelli-funds-llc/1685683.html.

Chemed Corp. Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Institutional Ownership by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.